DerNaPol

DerNaPol
Product Description

Chronic wounds are a major global health issue, costing billions in treatment annually (e.g., £3.2 billion in the UK 1in 2015; $28.1 to $96.8 billion in the USA in 20142). These wounds cause extreme sufferingwith severe symptoms, often complicated by antibiotic-resistant infections,impenetrablebiofilmsand deteriorating local tissue health.•The aim is to develop a nano-formulated product with antimicrobial, biofilm-disrupting, symptom-controlling, and wound-healing properties to address chronic wounds lacking effective treatment.•Goals of Preclinical Studies:oIdentify and Select Novel Repurposed Antimicrobial AgentsoOptimize Combinations for tissue health and reliefoEnhanceNano-Formulation to maximize therapeutic benefits

Read more Show less

Argent BioPharma ltd

  • GB
  • 2024
    On CPHI since
  • 1
    Certificates
  • 50 - 99
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
OTC
Pharmaceutical company
Start-up
Primary activities
API Producer
Biopharmaceutical
Custom Manufacturing/Custom Synthesis
OTC
View company profile
Categories
more categories Show less

Argent BioPharma ltd

  • GB
  • 2024
    On CPHI since
  • 1
    Certificates
  • 50 - 99
    Employees
Company types
Biopharmaceutical company
CMO/CDMO
OTC
Pharmaceutical company
Start-up
Primary activities
API Producer
Biopharmaceutical
Custom Manufacturing/Custom Synthesis
OTC
View company profile

More Products from Argent BioPharma ltd (6)

  • CimetrA®

    Product CimetrA®

    Early Stage Revenue Generating Immunomodulation Treatment for ARDS CimetrA® delivered 50,000 units to the USA market (Under Special Access) and over 100,000 worldwide, representing over US$2,500,000 in sales to date. Results of Preclinical and Clinical program, meeting FDA guidelines, to date: • Demon...
  • IrniCann®

    Product IrniCann®

    Pre-Clinical Stage Glioblastoma • Innovative pre-clinical stage drug targeting Glioblastoma Multiforme (GBM) Stem Cells, one of the deadliest forms of brain cancer, with the potential to transform treatment outcomes for this aggressive disease​ • An estimated 250,000 new cases of GBM per year worldwide....
  • CannEpil

    Product CannEpil

    CannEpil®, one of Argent BioPharma's flagship products, is an enhanced iteration of a compounded isolated cannabinoid formulation. It leverages well-known historical data to become one of the first compounded prescription investigational drugs used for seizure management over the past years. The active ing...
  • CimetrA

    Product CimetrA

    Early Stage Revenue Generating Immunomodulation Treatment for ARDS CimetrA® delivered 50,000 units to the USA market (Under Special Access) and over 100,000 worldwide, representing over US$2,500,000 in sales to date.
    Results of Preclinical and Clinical program, meeting FDA guide...
  • CogniCann

    Product CogniCann

    CogniCann® is an Investigational Medicinal Product based on two APIs, low CBD and high THC, designed to be used for symptoms associated with Dementia and Alzheimer's.

    A Phase II, randomized, double-blind cross-over, placebo-controlled clinical study designed to evaluate the clinical efficacy of ...
  • IrniCann

    Product IrniCann

    Pre-Clinical Stage Glioblastoma • Innovative pre-clinical stage drug targeting Glioblastoma Multiforme (GBM) Stem Cells, one of the deadliest forms of brain cancer, with the potential to transform treatment outcomes for this aggressive disease​• An estimated 250,000 new cases of GBM per year...

Argent BioPharma ltd resources (1)